









市場行情
/
股票
/
nasdaq-roiv
/

Roivant Sciences Ltd

ROIV

22.410USD

+0.620+2.85%

收盤 12/19, 16:00（美東）報價延遲15分鐘

15.46B總市值

虧損本益比TTM



Roivant Sciences Ltd

22.410

+0.620+2.85%

概覽公司財務分析

概覽

公司

財務

分析

關於 Roivant Sciences Ltd 公司

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Roivant Sciences Ltd簡介



公司代碼ROIV

公司名稱Roivant Sciences Ltd

上市日期Dec 03, 2020

CEOVenker (Eric)

員工數量750

證券類型Ordinary Share

年結日Dec 03

公司地址7Th Floor, 50 Broadway

城市LONDON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United Kingdom

郵編SW1H 0DB

電話4412955950

網址http://roivant.com/

公司代碼ROIV

上市日期Dec 03, 2020

CEOVenker (Eric)

Roivant Sciences Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Frank M. Torti, M.D.

President and Vant Chairman

13.74M

Dr. Keith S. Manchester, M.D.

Independent Director

1.93M

+0.76%

Dr. Eric Venker, M.D.

President and Immunovant Chief Executive Officer

1.34M

-0.52%

Mr. Richard Pulik

Chief Financial Officer

186.45K

-0.66%

Ms. Jennifer Humes

Chief Accounting Officer

112.25K

Mr. Ilan Oren

Independent Chairman of the Board

99.80K

+1.24%

Mr. James C. (Jim) Momtazee

Independent Director

92.14K

+0.69%

Mr. Matthew Gline

Chief Executive Officer, Director

82.26K

+4.20%

Ms. Melissa B. Epperly

Independent Director

40.50K

+2.68%

Mr. Daniel Gold

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Frank M. Torti, M.D.

President and Vant Chairman

13.74M

Dr. Keith S. Manchester, M.D.

Independent Director

1.93M

+0.76%

Dr. Eric Venker, M.D.

President and Immunovant Chief Executive Officer

1.34M

-0.52%

Mr. Richard Pulik

Chief Financial Officer

186.45K

-0.66%

Ms. Jennifer Humes

Chief Accounting Officer

112.25K

Mr. Ilan Oren

Independent Chairman of the Board

99.80K

+1.24%

收入明細

FY2025Q1

業務USD

名稱

營收

佔比

VTAMA

55.13M

0.00%

地區USD

名稱

營收

佔比

United States

55.13M

0.00%

業務

地區

業務USD

名稱

營收

佔比

VTAMA

55.13M

0.00%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Dexcel Pharma Technologies, Ltd.

14.79%

Fidelity Management & Research Company LLC

8.73%

Ramaswamy (Vivek)

6.77%

Morgan Stanley Investment Management Inc. (US)

5.85%

SB Investment Advisers (UK) Limited

5.80%

其他

58.07%

持股股東

佔比

Dexcel Pharma Technologies, Ltd.

14.79%

Fidelity Management & Research Company LLC

8.73%

Ramaswamy (Vivek)

6.77%

Morgan Stanley Investment Management Inc. (US)

5.85%

SB Investment Advisers (UK) Limited

5.80%

其他

58.07%

股東類型

持股股東

佔比

Investment Advisor

27.37%

Investment Advisor/Hedge Fund

19.48%

Hedge Fund

15.22%

Corporation

14.79%

Individual Investor

10.61%

Private Equity

9.04%

Research Firm

1.64%

Pension Fund

0.51%

Venture Capital

0.46%

其他

0.88%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

690

526.70M

77.13%

-109.19M

2025Q2

673

776.63M

112.42%

-147.35M

2025Q1

676

776.88M

113.63%

-136.03M

2024Q4

645

780.70M

109.07%

-147.12M

2024Q3

601

789.51M

107.30%

-83.47M

2024Q2

564

721.13M

95.89%

-110.95M

2024Q1

518

776.24M

96.43%

-47.46M

2023Q4

449

787.20M

97.95%

-13.44M

2023Q3

421

794.31M

100.15%

+12.61M

2023Q2

394

761.99M

100.91%

+10.72M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Dexcel Pharma Technologies, Ltd.

102.85M

15.06%

Jul 01, 2025

Fidelity Management & Research Company LLC

55.50M

8.13%

+3.83M

+7.41%

Jun 30, 2025

Ramaswamy (Vivek)

48.92M

7.16%

-1.78M

-3.50%

Sep 05, 2025

Morgan Stanley Investment Management Inc. (US)

33.37M

4.89%

+2.37M

+7.64%

Jun 30, 2025

SB Investment Advisers (UK) Limited

59.95M

8.78%

-1.90M

-3.07%

Jun 30, 2025

The Vanguard Group, Inc.

39.25M

5.75%

-1.44M

-3.53%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

35.53M

5.2%

-1.48M

-4.00%

Jun 30, 2025

QVT Financial LP

29.38M

4.3%

-36.41M

-55.34%

Jun 30, 2025

Viking Global Investors LP

34.24M

5.01%

-11.78M

-25.59%

Jun 30, 2025

Rubric Capital Management LP

20.37M

2.98%

+2.60M

+14.65%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco S&P MidCap 400 Pure Growth ETF

3.56%

Adaptiv Select ETF

2.91%

Virtus LifeSci Biotech Products ETF

2.79%

State Street SPDR S&P Biotech ETF

2.67%

WisdomTree US Value Fund

2.3%

ProShares Ultra Nasdaq Biotechnology

1.73%

Goldman Sachs Future Health Care Equity ETF

1.73%

Direxion Daily S&P Biotech Bull 3X Shares

1.41%

Invesco Nasdaq Biotechnology ETF

1.33%

WisdomTree BioRevolution Fund

1.3%

Invesco S&P MidCap 400 Pure Growth ETF

佔比3.56%

Adaptiv Select ETF

佔比2.91%

Virtus LifeSci Biotech Products ETF

佔比2.79%

State Street SPDR S&P Biotech ETF

佔比2.67%

WisdomTree US Value Fund

佔比2.3%

ProShares Ultra Nasdaq Biotechnology

佔比1.73%

Goldman Sachs Future Health Care Equity ETF

佔比1.73%

Direxion Daily S&P Biotech Bull 3X Shares

佔比1.41%

Invesco Nasdaq Biotechnology ETF

佔比1.33%

WisdomTree BioRevolution Fund

佔比1.3%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Roivant Sciences Ltd的前五大股東是誰？



Roivant Sciences Ltd的前五大股東如下：
Dexcel Pharma Technologies, Ltd.
持有股份：102.85M
佔總股份比例：15.06%。
Fidelity Management & Research Company LLC
持有股份：55.50M
佔總股份比例：8.13%。
Ramaswamy (Vivek)
持有股份：48.92M
佔總股份比例：7.16%。
Morgan Stanley Investment Management Inc. (US)
持有股份：33.37M
佔總股份比例：4.89%。
SB Investment Advisers (UK) Limited
持有股份：59.95M
佔總股份比例：8.78%。